Ya estamos en México para vivir el Roche Press Day 2025, en donde ampliaremos la conversación para llevar la innovación en salud a donde más se necesita, manteniendo siempre nuestro firme compromiso con la equidad de género. Unimos a periodistas, expertos y líderes para transformar juntos los sistemas de salud de la región. Únete tu también porque #todossumamos.
Info
Roche ist ein globales Unternehmen mit Vorreiterrolle in der Erforschung und Entwicklung von Medikamenten und Diagnostika und ist darauf fokussiert, Menschen durch wissenschaftlichen Fortschritt ein besseres, längeres Leben zu ermöglichen. Dank der Kombination von Pharma und Diagnostika unter einem Dach ist Roche führend in der personalisierten Medizin - einer Strategie mit dem Ziel, jeder Patientin und jedem Patienten die bestmögliche Behandlung zukommen zu lassen. Roche ist das grösste Biotech-Unternehmen weltweit mit differenzierten Medikamenten für die Onkologie, Immunologie, Infektionskrankheiten, Augenheilkunde und Erkrankungen des Zentralnervensystems. Roche ist auch der bedeutendste Anbieter von In-vitro-Diagnostika und gewebebasierten Krebstests und ein Pionier im Diabetesmanagement. Seit der Gründung im Jahr 1896 erforscht Roche bessere Wege, um Krankheiten zu verhindern, zu erkennen und zu behandeln und leistet einen nachhaltigen Beitrag zur gesellschaftlichen Entwicklung. Zum Ziel des Unternehmens gehört es durch Kooperationen mit allen relevanten Partnern den Zugang von Patienten zu medizinischen Innovationen zu verbessern. Auf der Liste der unentbehrlichen Arzneimittel der Weltgesundheitsorganisation stehen heute 30 von Roche entwickelte Medikamente, darunter lebensrettende Antibiotika, Malariamittel und Krebsmedikamente. Ausgezeichnet wurde Roche zudem bereits das neunte Jahr in Folge als das nachhaltigste Unternehmen innerhalb der Pharma-, Biotechnologie- und Life-Sciences-Branche im Dow Jones Sustainability Index. Die Roche-Gruppe mit Hauptsitz in Basel, Schweiz ist in über 100 Ländern tätig und beschäftigte 2017 weltweit rund 94 000 Mitarbeiterinnen und Mitarbeiter. Im Jahr 2017 investierte Roche CHF 10,4 Milliarden in Forschung und Entwicklung und erzielte einen Umsatz von CHF 53,3 Milliarden. Genentech in den USA gehört vollständig zur Roche-Gruppe. Roche ist Mehrheitsaktionär von Chugai Pharmaceutical, Japan. Weitere Informationen finden Sie unter www.roche.com/careers #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalizedHealthcare #GreatPlaceToWork #Innovation
- Website
-
http://www.roche.com/
Externer Link zu Roche
- Branche
- Biotechnologieforschung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Switzerland 🇨🇭
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- biotechnology, innovation, personalized healthcare, great place to work, diagnostics, pharmaceuticals, research, healthcare, personalised healthcare, diabetes care, genomics, healthcare technology, big data und Science
Orte
Beschäftigte von Roche
Updates
-
Join us in celebrating the incredible visionaries Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi, who have been honoured with the 2025 The Nobel Prize in Physiology or Medicine! Their discovery of the critical role of regulatory T cells advanced our understanding of immune balance, paving the way for therapies targeting autoimmune diseases, cancer, and stem cell transplant complications. This has established a transformative field in medicine. The work on "suppressor T cells" essentially revived and validated a previously abandoned field through rigorous experimentation and the eventual identification of regulatory T cells. A true story of perseverance! We firmly believe in the potential of this discovery for the future and that this science is transformative. Let's applaud these true pioneers for their groundbreaking achievements and their immense contributions to the advancement of medical science. Their dedication and innovation deserve nothing less than a resounding standing ovation! #NobelPrize #Immunology
-
-
In healthcare, moving from reactive to proactive management can change outcomes for patients. That’s why the first CE-marked AI tool for chronic kidney disease is such a milestone. 🚀 By analyzing routine clinical data, it supports risk stratification and helps identify patients at high risk of kidney function decline. This means clinicians gain deeper insights to guide more timely, personalized care — ensuring decisions are made with greater confidence. From early insights to informed decisions, AI is shaping the future of kidney health. 👉 From early insights to informed decisions — discover more: https://lnkd.in/drPqQRtb #HealthcareInnovation #DigitalHealth #AIinHealthcare #CKD #HealthTech
-
Descentralizar la salud significa algo más que acercar servicios: mejora la calidad de vida, alivia la presión hospitalaria y fortalece la prevención. Con innovación, integración de servicios y alianzas estratégicas, la región puede avanzar hacia modelos más sostenibles y centrados en las personas. #TodosSumamos
-
We believe in the power of inclusion to transform lives 🤝— accessibility is not just a “nice-to-have”; it’s a necessity—and a reflection of our commitment to welcoming everyone to thrive personally and professionally. Johanna, one of our incredible colleagues living with multiple sclerosis, shared her powerful story about the challenges and opportunities in her daily work. Her courage reminds us of something essential: 80% of disabilities occur during working life—and many go unseen. 💡 Let’s make sure the future includes everyone.✨ #Rochecareers #Accessibility #Inclusion #DisabilityAwareness
-
Roche hat dies direkt geteilt
CEO Roche Group | Passionate about science, and committed to positively impacting people’s lives through healthcare
A heartfelt congratulations to our colleague Hans Clevers on winning the prestigious Abarca Prize for his pioneering work on organoids! This award recognises the impact of medical-scientific advances and innovations, highlighting their importance for society worldwide. Hans’s work marks a true turning point for research. For decades, we studied cell lines on flat plastic dishes. The development of 3D simplified versions of human organs completely changed that, allowing us to ask questions about human biology and disease we could only dream of before. Organoids hold the promise to advance translational research and cutting-edge therapeutic innovations for the benefit of patients. Hans, we are proud to have you on our team. Your discoveries are helping to create a healthier future. Congratulations again on this well-deserved honour! Thanks to Mairene Coto Llerena, Ilya Lukonin, Héloïse MARY and Barbora Lavičková for sharing these images from their research. #FutureofHealthcare #MedicalResearch #AbarcaPrize #organoids
-
We are proud to celebrate Hans Clevers for receiving the Abarca Prize in Spain, a recognition that honors those in science who embody the humanistic and professional values of Dr. Juan Abarca Campal. Discover the full story here: https://spkl.io/6044ApTSe #AbarcaPrize #ResearchPrize #EarlyDevelopment
-
-
Roche hat dies direkt geteilt
CEO Roche Group | Passionate about science, and committed to positively impacting people’s lives through healthcare
I fully agree with Teresa Harris Graham: the conviction and momentum we are building at Roche is remarkable. The progress we have made has been extraordinary. We have advanced a record eight potentially practice-changing medicines into the final phase of development - tackling diseases with some of the highest societal burden, from oncology and neurology to hypertension and obesity. This ability to deliver for patients today while building for tomorrow is what will help us achieve our bold ambition: to prevent, stop and cure diseases. Thank you to everyone in our Pharma teams for your passion and dedication: you are making a real difference for patients and for the future of healthcare.
As the week draws to a close, I wanted to take a moment to reflect back on some of what I shared at our 2025 Investor Relations Pharma Day in London, as well as in several internal town hall discussions over the last few days, including: - The conviction we have in our diverse, best-in-disease on market portfolio and its continued growth potential, helping more and more patients around the world - How our portfolio is targeted in the right areas to help the most people. Our pipeline of medicines across five core therapeutic areas has the potential to be transformative in diseases that account for 60% of disease burden globally - Our strong entry into obesity and commitment to becoming a top three player - How we are making great strides in growing the capabilities needed to deliver on our future portfolio, and - My gratitude to the dedicated group of people across the entire Pharma division at Roche who are making it all happen, every day, for the patients who need the medicines we discover, develop and deliver around the world We are committed to bringing transformational medicines to patients and, just as importantly, we are committed to doing that in a way that is uniquely Roche – with rigour in the science, discipline in the business, and unwavering care for our patients and our people. I couldn’t be more #rocheproud
-
-
Given the significant burden cardiovascular and metabolic diseases impose on patients, caregivers, and society, #diagnostics play a vital role in actively addressing a key aspect of this challenge: heart attacks. Rapidly and accurately diagnosing heart attacks, while ruling out those who don’t have one, is key to providing the best care. This helps prioritize patients in the emergency department and ensures healthcare resources are used where they are needed most.
-
Healthcare is changing. The future is digital. At Roche, our Finance function is evolving with it. For our Finance function, this means blending human expertise with digital intelligence. We are moving beyond our traditional role as custodians of the numbers to enable smarter, faster decisions—transforming data from insight into foresight and deepening our strategic partnership with the business. To accelerate this journey, we recently brought 300 of our senior Finance leaders together for the Roche Finance Symposium. It was our moment to connect, shape our strategy, and lead our collective impact. At its core, this journey is about one thing: focusing our strategy and resources on what truly matters. Our commitment is clear — a digital-driven Finance function that accelerates innovation and delivers faster to patients in need. #FutureofFinance #Roche #Innovation
Verbundene Seiten
Ähnliche Seiten
Finanzierung
Roche
Insgesamt 4 Finanzierungsrunden
![]()
SoftBank
Weitere Informationen auf Crunchbase
Letzte Runde
Kapitalerhöhung nach Börsengang
Externer Crunchbase-Link für die letzte Finanzierungsrunde
5.000.000.000,00 $
Investor:innen